Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma

Recruiting now

Conditions studied: Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, DNA Methylation

In brief

Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.

Key facts

Study ID

NCT06490003

Run by

City of Hope Medical Center

People needed

150

Starts

2004-06-01

Expected to finish

2028-06-18

Last updated by the study team

2026-07-13

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who had histologically confirmed esophageal squamous cell carcinoma.
• Patients who had undergone chemotherapy.
• Patients receiving initial chemotherapy
• Written informed consent following full study information is provided to the patient.

You may not qualify if…

• Patients for whom a preoperative biopsy sample cannot be obtained
• Patients who cannot assess at 2 months later after chemotherapy.
• Patients with multiple cancers.

Where it is running

• Yamanashi Universiy — Chūō, Yamanashi, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.